Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:5603 |
Name | T-cell acute lymphoblastic leukemia |
Definition | An acute lymphoblastic leukemia that is characterized by too many T-cell lymphoblasts found in the bone marrow and blood. |
Source | DiseaseOntology.org |
Alt Ids | DOID:715 DOID:5599 |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia lymphoid leukemia acute leukemia acute lymphoblastic leukemia T-cell acute lymphoblastic leukemia |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
JAK3 M511I | Tofacitinib | T-cell acute lymphoblastic leukemia | sensitive | detail... |
JAK3 M511I | Ritlecitinib | T-cell acute lymphoblastic leukemia | sensitive | detail... |
JAK3 M511I | Selumetinib | T-cell acute lymphoblastic leukemia | sensitive | detail... |
JAK3 M511I | Dexamethasone + Tofacitinib | T-cell acute lymphoblastic leukemia | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02112916 | Phase III | Cyclophosphamide Vincristine Sulfate Ifosfamide Pegaspargase Methotrexate Cytarabine Mercaptopurine Thioguanine Leucovorin Daunorubicin Dexamethasone Bortezomib Etoposide Doxorubicin | Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma | Active, not recruiting | USA | CAN | 2 |
NCT02518113 | Phase Ib/II | Dexamethasone LY3039478 | A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL | Completed | USA | ITA | FRA | DEU | 1 |
NCT02535806 | Phase II | Vincristine Sulfate Bortezomib Pegaspargase Methotrexate Cytarabine Mitoxantrone Prednisone | Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults | Terminated | USA | 0 |
NCT02881086 | Phase III | Rituximab Doxorubicin Cytarabine Mercaptopurine Nelarabine Methotrexate Pegaspargase Cyclophosphamide Vindesine Vincristine Sulfate Daunorubicin Dexamethasone | Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment | Active, not recruiting | DEU | 0 |
NCT03081910 | Phase I | CD5 CAR T cells Cyclophosphamide + Fludarabine | Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA) | Recruiting | USA | 0 |
NCT03328104 | Phase I | Cyclophosphamide + Etoposide + Everolimus + Nelarabine | Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma (ENCERT) | Recruiting | USA | 0 |
NCT03590171 | Phase II | Bortezomib | International Study for Treatment of High Risk Childhood Relapsed ALL 2010 | Recruiting | ITA | FRA | BEL | AUT | 11 |
NCT03829540 | Phase I | CD4CAR | CD4CAR for CD4+ Leukemia and Lymphoma | Recruiting | USA | 0 |
NCT04128501 | Phase II | Azacitidine + Venetoclax | Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting | Recruiting | USA | 0 |
NCT04307576 | Phase III | Imatinib Blinatumomab Inotuzumab ozogamicin | A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia | Recruiting | FRA | DEU | BEL | 11 |
NCT04315324 | Phase II | OBI-3424 | Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) | Active, not recruiting | USA | 0 |
NCT04502446 | Phase I | CTX130 | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies | Recruiting | USA | CAN | 1 |
NCT04681105 | Phase I | Acetaminophen + Dexamethasone + Diphenhydramine + Flotetuzumab + Ranitidine Dexamethasone + Diphenhydramine + Flotetuzumab + Ibuprofen + Ranitidine | Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies | Recruiting | USA | 0 |
NCT04771572 | Phase I | LP-118 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | Recruiting | USA | 0 |
NCT04984356 | Phase Ib/II | WU-CART-007 | A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL | Recruiting | USA | 1 |
NCT05032183 | Phase Ib/II | Cytarabine + Filgrastim + Methotrexate + Rituximab + Tagraxofusp-erzs Cyclophosphamide + Dexamethasone + Mesna + Methotrexate + Rituximab + Tagraxofusp-erzs + Vincristine Sulfate Tagraxofusp-erzs | Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | Recruiting | USA | 0 |
NCT05038644 | Phase I | XmAb18968 | XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia | Recruiting | USA | 0 |
NCT05268003 | Phase II | Ponatinib Venetoclax | A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia | Recruiting | USA | 0 |
NCT05289687 | Phase II | Daratumumab and hyaluronidase-fihj | Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL | Recruiting | USA | 0 |
NCT05292664 | Phase I | Azacitidine + Cytarabine + Hydrocortisone + Leucovorin + Methotrexate + Venetoclax Calaspargase pegol-mknl + Cytarabine + Dexamethasone + Dexrazoxane + Doxorubicin + Hydrocortisone + Leucovorin + Methotrexate + Venetoclax + Vincristine Sulfate Azacitidine + Venetoclax | Venetoclax Basket Trial for High Risk Hematologic Malignancies | Recruiting | USA | 0 |
NCT05464836 | Phase II | CB-103 + Venetoclax | Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL | Recruiting | USA | 0 |
NCT05581030 | Phase I | Calaspargase pegol-mknl + Cyclophosphamide + Dexamethasone + Doxorubicin + Rituximab + Vincristine Sulfate Cytarabine + Methotrexate Calaspargase pegol-mknl + Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine Sulfate | CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) | Recruiting | USA | 0 |